OFF-LABEL USE INFORMATION DISSEMINATION COULD BE BALANCED BY FDA RULEMAKING UNDER LATEST HOUSE BILL; UNAPPROVED DOSE INFORMATION EXPLICITLY ALLOWED
FDA would be authorized to create a regulatory process to handle situations in which it felt that promotion of off-label uses should be accompanied by balancing information, according to the most recent version of the House FDA drugs/biologics reform bill (HR 3199).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth